ResearchResearch summary
Candida biofilm findings in recurrent vaginal yeast infection
Isolates from recurrent vaginal yeast infections had higher biomass in vitro; XTT and confocal comparisons were not significant; no treatment was tested.
In this pathway
- Current topic
- Candida biofilm findings in recurrent vaginal yeast infectionCurrent

Sources behind these conclusions
Claim: Candida can form biofilms in defined device-associated and mucosal infections, but demonstrating this biology in those settings does not establish a hidden intestinal biofilm or broad multisystem Candida syndrome in a person with nonspecific symptoms.
Supported · Moderate — CDC catheter guidance and the IDSA candidiasis guideline recognize Candida adherence, extracellular matrix, reduced antimicrobial susceptibility, and the clinical importance of source control in defined device-associated infection. Current biofilm synthesis also describes mucosal and device models. A prospective single-center cohort found higher in-vitro crystal-violet biomass among vaginal isolates from the group with recurrent vulvovaginal candidiasis (RVVC), while XTT activity and a selected confocal-area comparison were not statistically significant; these isolate assays do not measure vaginal biofilm in vivo. A retrospective oncology-center candidemia cohort adds a patient-outcome association for high-level in-vitro biofilm in the treated subgroup (adjusted HR 6.59, 95% CI 1.87-23.24), but only nine high-level isolates were present overall, the binary comparison was not significant, and the paper's patient/case denominator is unclear. This observational subgroup result does not establish causation or a treatment effect. None of these sources validates nonspecific symptoms as a test for an intestinal biofilm or permits device-associated findings to be transferred to a broad outpatient syndrome.
Sources for this claim
- Background Information: Pathogenesis — Guidelines for the Prevention of Intravascular Catheter-Related Infections (Guideline)
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America (Guideline)
- Natural-Compound Adjuvants Dismantle Candida Biofilms: Mechanisms, Design Rules, and Biofilm-Aware Pharmacology (Other)
- New insights in the role of Candida biofilm in the pathogenesis of recurrent vulvovaginal candidiasis: a prospective clinical study (Observational study)
- Biofilm formation and increased mortality among cancer patients with candidemia in a Peruvian reference center (Observational study)
Bottom line
This prospective cohort found higher in-vitro crystal-violet biofilm biomass among vaginal Candida isolates from the RVVC group than the non-RVVC group. XTT activity and the smaller confocal-area comparison were not significantly different, and no treatment was tested.
Why this source matters
The study connects patient-reported recurrence status with laboratory measurements from vaginal Candida isolates. It adds a prospective clinical-isolate comparison to biofilm research, while keeping the measured phenotype separate from biofilm burden in a person's vagina or any treatment effect.
Study and population
This prospective observational study enrolled 271 adults with Candida spp. recovered from vaginal swabs at the sexually transmitted diseases consultation service of a tertiary teaching hospital in Madrid, Spain. The median age was 34 years (IQR 26–45). Nineteen patients were classified as having recurrent vulvovaginal candidiasis (RVVC) and 252 as non-RVVC. Participants were enrolled from October 2021 to October 2022 and followed for another year, through October 2023. The RVVC group definition was at least 3 symptomatic episodes in a year, but not every episode was culture-confirmed.
What was tested
Researchers tested the first vaginal Candida isolate recovered from each patient. Crystal-violet absorbance measured biomass and XTT absorbance measured metabolic activity after 24 hours in a laboratory biofilm model, with triplicate assays. Confocal microscopy measured the area occupied by biofilm in 16 RVVC isolates and 16 arbitrarily selected, species-matched non-RVVC isolates. No biofilm-disrupting product, antifungal regimen, or other intervention was assigned.
Results
Fifty-five of 271 patients (20.3%) reported at least one recurrence; 19/271 (7.0%) met the study's RVVC-group definition and reported 65 episodes.
For crystal-violet biomass, 18/19 RVVC isolates had a median absorbance of 1.850 (IQR 1.578–2.156), compared with 1.426 (1.081–1.823) among 238/252 non-RVVC isolates (p=0.005). For XTT metabolic activity, the same 18/19 and 238/252 isolates had medians of 0.184 (0.116–0.293) and 0.228 (0.147–0.331), respectively (p=0.253); this difference was not statistically significant.
Confocal area was assessed in 16/19 RVVC isolates and 16 selected, species-matched non-RVVC isolates. Median occupied area was 13.15% (IQR 8.54–16.49) versus 10.73% (5.88–17.73) (p=0.710), also not statistically significant. C. albicans accounted for 90.0% of isolates overall; it was reported in 73.7% of RVVC and 91.3% of non-RVVC isolates (p=0.029). One abstract sentence gives 73.3% for the RVVC group, while the Results and Table 1 give 73.7%; this summary uses the Results and Table 1 value.
The overall symptom comparison was not significant (p=0.258), and prior antifungal use was 5/19 versus 33/252 (p=0.160). Neither comparison estimates a treatment effect.
Applicability
The findings apply to group-level associations between in-vitro measurements of vaginal Candida isolates and reported RVVC status in this adult, single-center Spanish cohort. They do not show how much biofilm was present in a person's vagina, explain an individual's recurrence, identify treatment failure or resistance, or support broad intestinal or whole-body Candida claims.
Limitations
Only 19 patients were in the RVVC group, and the study reported no sample-size calculation or prespecified primary outcome. Classification relied mainly on reported symptoms; not every episode was culture-confirmed. CV and XTT assays included 256/271 isolates (18/19 RVVC and 238/252 non-RVVC), while confocal microscopy included 16/19 RVVC isolates and 16/252 arbitrarily selected, species-matched non-RVVC isolates. The 24-hour laboratory measurements are not in-vivo vaginal biofilm measurements. The study did not test a disruptor or treatment and cannot establish cause, diagnosis, prognosis, or treatment benefit. E. coli co-isolation was assessed in only 81/271 samples, with no RVVC samples available for that test. Table 1's total count for moderate symptoms conflicts with its component counts, so no total is inferred.
Contribution to the evidence
Contextual. The cohort adds a prospective patient-level comparison in which in-vitro crystal-violet biomass was higher among RVVC isolates, but XTT activity and the selected confocal-area comparison were not significantly different. It informs the defined mucosal context without measuring biofilm in vivo or changing the linked map's verdict, evidence level, safety status, or practical action.
Practical change
No practical change. The study did not evaluate an intervention, diagnostic test, or care route. Its isolate-assay association is not a reason to add a biofilm disruptor or change treatment.
Funding and conflicts
Funding came from Fundación Mutua Madrileña (FMM24/01), IiSGM (2022-PI-II-COOPTR-01), and ISCIII/FEDER (PI21/00344), with named Miguel Servet and ISCIII support for M. Guembe, P. Escribano, and M. Díaz-Navarro. JG reported speaking and lecture fees from Pfizer, Gilead Sciences, and Merck Sharp & Dohme UK. Other authors reported no commercial or financial relationships that could be construed as conflicts. One author disclosed Frontiers editorial-board membership at submission and stated it did not affect peer review.
Source
Read the original publication (published 27 March 2025; Frontiers in Microbiology. 2025;16:1566171).
Study type, population, and sample scale
- Study type
- Prospective single-center observational clinical-isolate cohort with in-vitro biofilm assays
- Population
- Adults aged 18 years or older with Candida spp. recovered from vaginal swabs at a tertiary teaching hospital in Madrid, Spain; recurrent vulvovaginal candidiasis (RVVC) classification used reported symptomatic episodes and did not verify every episode by culture.
- Sample scale
- 271 patients (19 RVVC and 252 non-RVVC); CV/XTT assays included 18/19 and 238/252 isolates; CLSM included 16/19 RVVC isolates and 16 selected non-RVVC isolates.
Results
- Of 271 patients, 19/271 (7.0%) met the study RVVC-group definition; 55/271 (20.3%) reported at least one recurrence, and the RVVC group reported 65 episodes. The study used at least 3 symptomatic episodes per year, but not every episode had culture confirmation.
- Crystal-violet biomass was measured in 18/19 RVVC isolates and 238/252 non-RVVC isolates. Median absorbance was 1.850 (IQR 1.578–2.156) versus 1.426 (1.081–1.823), respectively (p=0.005).
- XTT metabolic activity used the same denominators: 18/19 versus 238/252. Median absorbance was 0.184 (IQR 0.116–0.293) versus 0.228 (0.147–0.331) (p=0.253), a nonsignificant difference.
- Confocal microscopy measured occupied area in 16/19 RVVC isolates and 16 arbitrarily selected, species-matched non-RVVC isolates. Median area was 13.15% (IQR 8.54–16.49) versus 10.73% (5.88–17.73) (p=0.710), not a statistically significant difference.
- C. albicans accounted for 90.0% of isolates overall and 73.7% in the RVVC group versus 91.3% in the non-RVVC group (p=0.029). One abstract sentence reports 73.3%; the Results and Table 1 report 73.7%, used here.
- Overall symptom categories did not differ significantly between groups (p=0.258); prior antifungal use was 5/19 versus 33/252 (p=0.160). These are descriptive group comparisons, not treatment effects.
Limitations
- The study classified 19 patients as RVVC and followed the clinical-isolate cohort at one tertiary hospital in Madrid.
- It was a small, single-center observational study without a reported sample-size calculation or prespecified primary outcome; episode classification relied mainly on patient reports and not every episode was culture-confirmed.
- Biofilm biomass and metabolic activity were measured after 24 hours using the first recovered isolate per patient; confocal area was measured in 32 isolates.
- These in-vitro assays do not measure biofilm in the vagina, establish causation, show diagnostic performance, or test treatment. The non-RVVC confocal subset was arbitrarily selected and species-matched.
- CV and XTT assays included 256/271 isolates (18/19 RVVC and 238/252 non-RVVC); confocal microscopy included 16/19 RVVC and 16/252 selected non-RVVC isolates.
- Isolates were unavailable for CV/XTT in 15/271 patients, and the smaller confocal subset may not represent either group. E. coli co-isolation was assessed in only 81/271 samples, with no RVVC samples available for that test.
- Table 1 reports moderate symptoms in 6/19 RVVC and 37/252 non-RVVC patients, while its total count is inconsistent with those component counts.
- Do not infer a total moderate-symptom count from that table. The abstract also has one conflicting C. albicans percentage; the Results and Table 1 report 73.7% for RVVC, used in this summary.
Applies to
- Group-level associations between in-vitro biofilm measurements from vaginal Candida isolates and reported RVVC status in this adult Spanish clinic cohort
Does not apply to
- Biofilm burden measured in a person's vagina; an individual diagnosis, prognosis, or explanation for recurrence; treatment failure or antifungal resistance; benefit or safety of a biofilm-disrupting product; broad intestinal or whole-body Candida claims
Contribution to the current conclusion
Contextual
The cohort adds a prospective human vaginal-isolate comparison to the defined-site biofilm evidence. Crystal-violet biomass was higher in the RVVC group, while XTT metabolic activity and the selected confocal-area comparison were not significantly different. These 24-hour in-vitro assays do not measure vaginal biofilm burden in vivo, establish that biofilm causes recurrence, test a disruptor, or change practical guidance.
Related evidence mapPractical change or no change
No practical change. The study adds a limited in-vitro association between isolate biomass and reported RVVC status, but does not establish an in-vivo vaginal biofilm, causation, diagnosis, treatment benefit, or a reason to change care.
Funding and conflicts
- Funding
- The study was funded by Fundación Mutua Madrileña (FMM24/01), IiSGM (2022-PI-II-COOPTR-01), and ISCIII/FEDER (PI21/00344). Miguel Servet support (MSII18/00008) supported M. Guembe and (CPII20/00015) supported P. Escribano; M. Díaz-Navarro received ISCIII support (FI22/00022).
- Conflicts
- JG reported speaking and lecture fees from Pfizer, Gilead Sciences, and Merck Sharp & Dohme UK. The other authors reported no commercial or financial relationships that could be construed as conflicts. One author disclosed Frontiers editorial-board membership at submission and stated it did not affect peer review.
- Paper date
- 2025-03-27